Rein Therapeutics Inc.
RNTX
$1.40
-$0.08-5.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 47.77% | 0.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.07% | 22.50% | |||
| Operating Income | 20.07% | -22.50% | |||
| Income Before Tax | 18.19% | -24.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.19% | -24.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.19% | -24.01% | |||
| EBIT | 20.07% | -22.50% | |||
| EBITDA | 20.06% | -22.83% | |||
| EPS Basic | 24.93% | -12.35% | |||
| Normalized Basic EPS | 24.96% | -12.36% | |||
| EPS Diluted | 24.93% | -12.35% | |||
| Normalized Diluted EPS | 24.96% | -12.36% | |||
| Average Basic Shares Outstanding | 8.99% | 10.37% | |||
| Average Diluted Shares Outstanding | 8.99% | 10.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||